ReviewPolymers2026
Chitosan and Chitin-Derived Biomaterials in Orthopedics: A Structured Narrative Review of Polymer Design, Quantitative Performance, and Clinical Translation.
Review in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan and chitin-derived biomaterials, including native chitosan and chemically modified derivatives, have been widely investigated across orthopedic tissue engineering, implant functionalization, infection control, local delivery, and interface repair, but the evidence is dispersed across heterogeneous formats and indications. This single-author structured narrative review synthesizes 258 unique publications and interprets chitosan through a polymer design, quantitative performance, and clinical translation framework. Literature was identified (January-May 2026) using PubMed/MEDLINE as the primary database, with targeted verification in Web of Science, Scopus, and Google Scholar; no formal risk-of-bias or certainty grading was performed. Chitosan was studied as scaffolds, hydrogels, coatings, nanoparticles, microspheres, fibers, bioadhesives, bone-cement additives, cartilage adjuncts, tendon-to-bone systems, and intervertebral disk biomaterials. The highest human clinical evidence supported BST-CarGel/chitosan-blood implant augmentation of knee marrow stimulation, where randomized, 5-year, and biopsy data favored structural repair over microfracture alone; most other applications-bone regeneration, coatings, osteomyelitis hydrogels, bone cements, tendon/rotator cuff systems, and disk biomaterials-remain preclinical or translational-preclinical. Chitosan should be interpreted as a tunable polymer platform, not a single material; translation requires chemistry-defined formulation, indication-specific mechanical qualification, clinically relevant comparators, and standardized reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.